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Abstract
Introduction. Assessment of the clinical course of patients with acute pulmonary embolism (PE) and a right heart 
thrombus (RiHT).
Material and methods. The analysis included 13 consecutive patients with echocardiographically detected RiHT and 
acute PE who were treated in our department. The endpoints were 30-day all-cause mortality and 30-day acute PE-rela-
ted mortality. When a clear alternative cause of death was reported, a non-acute PE-related death was diagnosed and 
this contributed to 30-day all-cause mortality. All other fatalities were classified as related to acute PE.
Results. High risk acute PE was diagnosed in 4 of 13 patients, and intermediate risk acute PE was diagnosed in the 
remaining 9 patients. Thrombolysis was the first-choice treatment in 4 (31%) patients, 6 (46%) patients were only anti-
coagulated, and the remaining 3 (23%) patients underwent surgical treatment. The main indication for embolectomy 
was RiHT entrapped in a patent foramen ovale (PFO). Two patients died during the first 30 days; they were hemodyna-
mically unstable and deaths occurred within 48 hours since the diagnosis. No hemodynamically stable patients died 
within 30 days since the diagnosis.
Conclusions. Thirty-day mortality in patients with RiHT depended mostly on the patient’s clinical condition and was not 
related to the presence or morphology of the thrombus. Patients with shock or hypotension may possibly benefit more 
from primary invasive treatment compared to drug therapy.
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Introduction
Continuous progress in the diagnosis and treatment of acute 
pulmonary embolism (PE) allows increasingly efficient and 
effective patient care. However, lack of reliable clinical evi-
dence still makes treatment decisions challenging in some 
situations, such as the presence of a right heart thrombus 
(RiHT). RiHT is diagnosed in about 4% of patients with acute 
PE [1] but its rate during the first 24 hours since admission 
in hemodynamically unstable patients may be as high as 
18% [2]. Identification of RiHT in patients with clinically 
suspected acute PE allows the diagnosis and requires treat-
ment to be initiated but the optimal management approach 
has not been established. As stated in the European guide-
lines on the diagnosis and management of acute PE, the 
presence of RiHT is associated with worse outcomes [3]. In 
the recently reported Italian IPER registry that included 57 
patients with RiHT, the latter was not found to be associate 
with early in-hospital mortality [4]. Some other studies also 
did not report an increased mortality in patients with acute 
PE and RiHT [5, 6]. The multicentre Right Heart Thrombi 
European Registry (RIHTER) included 138 patients with RiHT 
to evaluate the prognostic importance of the size, mobility, 
and shape of RiHT in relation to other prognostic factors in 
patients with acute PE. This registry showed that patient 
outcomes depend mostly on the hemodynamic consequen-
ces of acute PE and not the shape, size, or mobility of the 
thrombus [7]. In this study, we reported in more details the 
characteristics and clinical course of patients with PE and 
RiHT who were investigated and treated in our centre. Some 
of these findings has been already covered in the summary 
of the RIHTER registry results [7].
Material and methods
We studied subsequent 13 patients with echocardio-
graphically detected RiHT and acute PE who were treated 
in our department. This patient group comprised 2% of 
746 patients with confirmed acute PE who were treated 
in our department during the same period. Parameters 
that characterized the hemodynamic status on admission 
included systolic blood pressure (SBP), presence of shock 
or hypotension, the sPESI (simplified pulmonary embolism 
severity index) score [8], presence and severity of right ven-
tricular overload by echocardiography, the shock index (SI) 
defined as the ratio of heart rate to systolic blood pressure, 
and laboratory markers of myocardial damage, i.e. blood 
levels of cardiac troponins and N-terminal B-type natriu-
retic propeptide (NT-proBNP) (Table 1). Two management 
approaches were identified — aggressive (thrombolysis 
and/or invasive treatment) and conservative, i.e., antico-
agulation only.
In accordance to the ESC guidelines, hypotension was 
defined as SBP < 90 mm Hg not due to other causes, such 
as acute arrhythmia, hypovolemia, or sepsis [3]. The sPESI 
score was calculated as the individual sum of scores for 
each criterion: age > 80 years, oxygen saturation < 90%, 
SBP < 100 mm Hg, heart rate > 110 bpm, and the presence 
of chronic heart failure or chronic lung disease [8]. Patients 
without these conditions were considered low-risk PE. Right 
Table 1. Clinical characteristics of the patients
Parameter RiHT+ 
N = 13
Fatalities 
N = 2*
Survivors 
N = 11
Age [years] 57.8 ± 25.9 78 and 64 years 55.4 ± 27.5
Gender (F/M) 7/6 2/0 5/6
SaO2 [%] 92.3 ± 6.3 96 and 83 93.0 ± 6.0
SBP [mm Hg] 106.1 ± 28.4 70 and 80 111.8 ± 27.1
HR [bpm] 100.3 ± 18.4 115 and 110 98.1 ± 19.2
SI ([bpm]/[mm Hg]) 1.0 ± 0.4 1.6 and 1.4 0.9 ± 0.3
sPESI > 0, n [%] 11 (85) 2 (100) 9 (82)
Concomitant diseases, n [%]** 5 (38) 1 (50) 4 (36)
Tn (+)*** 7 (54) 2 (100) 5 (45)
NT-proBNP > 500 [pg/mL] 8 (62) 1 (50) 7 (64)
Severity of acute PE: high/moderate/low risk (n) 4/9/0 2/0/0 2/9/0
DVT, n [%] 8 (62) 2 (100) 6 (54)
*Data as absolute values; **Concomitant conditions: malignancy, COPD, heart failure; ***Tn (+): troponin I or T level > 0.1 ng/mL, high-sensitivity troponin T level above the upper limit of the reference 
range for a given method; RiHT — right heart thrombus; F — female; M — male; SaO2 — oxygen saturation; SBP— systolic blood pressure; HR — heart rate; SI — shock index; sPESI — simplified pulmonary 
embolism severity index; NT-proBNP — N-terminal B-type natriuretic propeptide; PE — pulmonary embolism; DVT — deep vein thrombosis; COPD — chronic obstructive pulmonary disease
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ventricular overload by echocardiography was defined as 
the RV/LV dimension ratio in the 4-chamber view > 0.9, 
presence of the McConnell sign, or interventricular septum 
flattening and paradoxical motion. Laboratory markers of 
right ventricular overload included elevated NT-proBNP level 
(> 500 pg/mL) and troponin T or I level above 0.1 ng/mL, 
or high-sensitivity troponin T level above the upper limit of 
the laboratory-specific reference range [9]. Based on the 
European Working Group on Echocardiography report, three 
types of thrombus morphology were distinguished — oblong, 
oval, and mural [10].
The diagnosis of PE was based on multidetector row 
computed tomography imaging (16-slice GE LightSpeed 
Pro and 64-slice Toshiba Aquilion). Acute PE was diag-
nosed when thrombi were identified in at least segmental 
pulmonary arteries.
The endpoints were 30-day acute PE-related mortality 
and 30-day all-cause mortality. When a clear alternative 
cause of death was reported, such as sepsis or massive 
haemorrhage, a non-PE-related death was diagnosed. All 
other fatalities were classified as related to PE.
Statistical analysis
Statistical analysis was performed using the STATISTICA 
2011 and MedCalc software. Dichotomous variables were 
compared using the chi-square test. Nonlinear variables 
were compared using the nonparametric Mann-Whitney 
U test. Predictors of mortality were determined using logis-
tic regression. Cut-off points with highest sensitivity and 
specificity were determined using ROC curves. P < 0.05 
was considered statistically significant. The study protocol 
was approved by the Bioethics Committee at the Medical 
University of Warsaw.
Results
Clinical characteristics
Right heart thrombus was identified in 13 patients, includ-
ing mostly oblong RiHT (69%) and one mural thrombus. 
Except for one case, most (92%) thrombi were mobile. 
In two patients, the thrombus was entrapped in a patent 
foramen ovale (PFO) and protruded to the left atrium. At 
the diagnosis of RiHT, four patients were hemodynami-
cally unstable (high risk PE), and moderate risk PE was 
diagnosed in the remaining 9 patients based on the 
evidence of right ventricular overload and increased 
cardiac markers.
Clinical course
Management of patients with RiHT
Thrombolysis was the first-choice treatment in 4 (31%) 
patients (alteplase 100 mg over 2 hours in 3 patients; in 
the fourth patient, the dose was reduced to 70 mg over 
2 hours due to an increased bleeding risk), 3 (13%) pa-
tients underwent surgical treatment, and the remaining 6 
(46%) patients were only anticoagulated (Table 2).
High risk PE by the ESC definition was the reason for 
thrombolytic therapy in 2 patients [3]. In the remaining 
2 patients, moderate risk PE was diagnosed and throm-
bolytic therapy was administered due to no improvement 
despite intravenous unfractionated heparin infusion for 
several hours. One death was noted in the group treated 
with thrombolysis — a 78-year-old women (patient No. 1) 
treated due to high risk PE. The cause of death was recur-
rent pulmonary embolism due to heparin-induced throm-
bocytopenia (HIT). Due to thrombocytopenia, the patient 
was not considered a candidate for surgical treatment, 
and repeated thrombolysis was administered due to shock. 
The clinical course was also notable in the other unstable 
patient, a 27-year-old male with multiple endocrine neo-
plasia type 1 (MEN I) and active pituitary adenoma. Due to 
morbid obesity and high operative risk, thrombolysis was 
administered despite the presence of intracranial tumour, 
with very good treatment outcomes.
The decision to proceed with surgical treatment was 
made mainly due to the presence of a thrombus entrapped 
in a patent foramen ovale (PFO) and protruding to the left 
atrium (in 2 patients — No. 6 and 11). In addition, one 
patient (No. 7) was treated surgically due to a very large 
thrombus size and critical condition. This patient had sepsis 
associated with the presence of indwelling haemodialysis 
catheter and severe respiratory failure that required ven-
tilatory support. In addition, this patient underwent graf-
tectomy of a transplanted kidney one week before acute 
PE was diagnosed, which increased the risk of bleeding in 
case of thrombolytic treatment. Of note, none of surgically 
treated patients died during 30 days since the diagnosis 
of RiHT, and one death during further follow-up was not 
related to acute PE.
The remaining patients received anticoagulation only. 
This group included 2 patients with high-risk PE in whom 
more aggressive treatment was contraindicated. One of 
these patients had disseminated malignancy with multi-
ple metastases, including in the central nervous system. 
This patient was not a candidate for causal treatment of 
malignancy at the time of the diagnosis of acute PE and 
died after 3 days of treatment. The other patient with high 
risk PE who received anticoagulation only was an 85-year- 
-old critically ill woman, bedridden for 6 months before the 
diagnosis of acute PE, with severe acute kidney injury at 
the time of the diagnosis. This patient died in the fourth 
month of the hospital stay due to worsening uraemia. Due 
to her poor general condition, she was not considered 
a candidate for renal replacement therapy.
Predictors of mortality
Two patients (15%) died during the first 30 days; they 
were hemodynamically unstable, in an advanced age 
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Table 2. Clinical characteristics and the clinical course in patients with the right heart thrombus (RiHT)
No. Gender, 
age 
[years]
Characteristics RiHT Treatment and clinical course
1 F 
78
High risk acute PE 
SBP 70 mm Hg 
HR 115 bpm 
SI 1.6
Oblong, highly mobile,  
10 × 40 mm
Patient successfully treated with rt-PA 0.6 mg/kg due to high-risk 
acute PE. HIT diagnosed on the 8th day of heparin treatment, with 
recurrent acute PE (fondaparinux was initiated). Acute worsening 
after 3 days, RiHT was diagnosed, the patient was not considered 
a candidate for surgical treatment, treated with repeated rt-PA ad-
ministration, died in 4th day after the diagnosis of RiHT
2 M 
26
High risk acute PE 
SBP 70 mm Hg 
HR 115 bpm 
SI 1.6
In the right atrium and 
the right ventricle, 
oblong, highly mobile, 
10 × 70 mm, TEE: RiHT 
without communication 
with PFO
Morbid obesity BMI 55.6 kg/m2, MEN I, pituitary adenoma, treated 
with rt-PA 100 mg/2 h i.v., followed by UFH for 3 days, LMWH and 
VKA. Follow-up echo at 24 h — no RiHT, discharge home in good 
clinical condition at 8th day of treatment
3 F 
85
High risk acute PE 
SBP 80 mm Hg 
HR 100 bpm 
SI 1.25
Length approx. 30 mm, 
oblong, moderately 
mobile
Acute prerenal kidney injury, eGFR 22 mL/min/1.73 m2, thromboly-
tic treatment was not administered due to generally poor condition 
of the patient (immobilisation, cachexia), treated with UFH for 
3 days, followed by LMWH, with clinical improvement, follow-up 
echo at 72 h — RiHT still present, later without RiHT. The patient 
died in the 4th month of hospital stay due to sepsis complicated by 
multiorgan failure
4 F 
64
High risk acute PE 
SBP 80 mm Hg 
HR 110 bpm 
SI 1.375
Length > 50 mm, oblong, 
highly mobile, protruding 
through PFO to the left 
atrium
Disseminated malignancy during palliative chemotherapy, CNS 
metastases, massive proximal lower limb deep venous thrombosis. 
Follow-up echo at 2 days of treatment — persisting RiHT. Treated 
with UFH i.v., died after 3 days of treatment
5 M 
37
Moderate risk 
acute PE 
SBP 120 mm Hg 
HR 100 bpm 
SI 0.8
12 × 67 mm, highly 
mobile, oblong, in the 
right atrium and the right 
ventricle
Celiac disease, chronic hepatitis C. Treated with rt-PA 100 mg/2 h 
i.v. due to large size and mobility of RiHT, followed by UFH for 
3 days, LMWH and VKA, follow-up echo at 48 h — no RiHT, dischar-
ged home at 7th day after thrombolysis
6 F 
74
Moderate risk 
acute PE 
SBP 150 mm Hg 
HR 65 bpm 
SI 0.4
8 × 40 mm, oblong, 
highly mobile, entrapped 
in PFO
Hyperthyroidism treated with thiamazole, chronic kidney disease 
eGFR 54 mL/min/1.73 m2. Surgical treatment with removal of 
the thrombus, followed by LMWH, discharged home at 14th day in 
a good general condition
7 M 
27
Moderate risk 
acute PE 
SBP 90 mm Hg 
HR 120 bpm 
SI 1.3
10 × 47 mm, oblong, 
highly mobile in the right 
ventricle
History of kidney transplantation, graftectomy 2 days before diag-
nosis of RiHT, renal replacement therapy — haemodialysis, sepsis, 
acute respiratory failure. Surgical treatment on the 4th day due to 
worsening of the clinical conditions and contraindications to throm-
bolysis, follow-up echo at 7th day of treatment — no RiHT, died in 
the 4th month of intensive care due to worsening respiratory failure 
secondary to recurrent treatment-resistant sepsis
8 F 
79
Moderate risk 
acute PE 
SBP 110 mm Hg 
HR 75 bpm 
SI 0.7
8 × 16 mm, immobile, 
mural
Diabetes type 2, rheumatoid arthritis. Treated with LMWH, follow-
-up echo at 72 h — no RiHT, discharged home at 6th day in a good 
general condition
9 M 
84
Moderate risk 
acute PE 
SBP 100 mm Hg 
HR 84 bpm 
SI 0.84
17 × 24 mm, oval, mo-
derately mobile, another 
thrombus 21 × 17 mm 
attached to a pacemaker 
lead, oblong, mobile in 
the right ventricle
Heart failure NYHA class III, LVEF approx. 25%, diabetes type 2, 
acute kidney injury, permanent atrial fibrillation. Treated with 
LMWH, follow-up echo at 72 h — persisting RiHT, discharged home 
at 14th day in an improved condition without RiHT (resolution in 
follow-up echo at 8th day)
→
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and with significant comorbidities (malignancy, chronic 
obstructive pulmonary disease [COPD]). No hemody-
namically stable patients died within 30 days since the 
diagnosis of RiHT.
Discussion
Right heart thrombi are present in about 4% of patients 
with acute PE [1, 3, 4, 6, 11] but this rate increases to 
about 18% [2] to 22% [12] in patients hospitalized in 
intensive care units. In our centre, the rate of RiHT in pa-
tients with acute PE was about 2% (13 of 746 subsequent 
patients). The authors of the guidelines on the diagnosis 
and treatment of acute PE noted that the presence of RiHT 
is associated with worse treatment outcomes [3]. Accor-
ding to other reports, treatment outcomes in patients with 
RiHT are comparable to those in the general population 
of acute PE patients [4–6]. Due to lack of randomized 
studies, it is difficult to establish the effect of RiHT on 
prognosis. For the same reason, it is controversial whether 
RiHT is an independent risk factor of early mortality. The 
RIHTER registry was an attempt to determine the effect 
of RiHT on treatment outcomes in patients with acute 
PE [7]. Data on 138 patients with RiHT were compared 
10 M 
67
Moderate risk 
acute PE 
SBP 100 mm Hg 
HR 110 bpm 
SI 1.1
Length 14 mm, oval, mo-
derately mobile
Heart failure NYHA class II, LVEF approx. 25%, thrombolysis follo-
wed by treatment with LMWH and VKA, follow-up echo at 24 h — no 
thrombus, discharged home at 6th day in a good general condition
11 M 
21
Moderate risk 
acute PE 
SBP 120 mm Hg 
HR 120 bpm 
SI 1.0
24 × 9 mm, oblong, 
highly mobile, protruding 
through PFO to the left 
atrium
Urgent surgery due to worsening hemodynamic status and RiHT 
communication with PFO, followed by LMWH and VKA, follow-up 
echo at one week after the surgery — no thrombus, discharged 
home at 24th day in a good general condition
12 F 
26
Moderate risk 
acute PE 
SBP 140 mm Hg 
HR 110 bpm 
SI 0.8
20 × 20 mm, oval, mode-
rately mobile, TEE: RiHT 
confirmed, without com-
munication with PFO
Morbid obesity, nephrotic syndrome. UFH for 3 days followed by 
LMWH, follow-up echo at day 3 and 11 — smaller RiHT, discharged 
home at 12th day with RiHT in a good general condition. Follow-up 
echo after several months — much smaller mass, malignancy was 
excluded
13 F 
83
Moderate risk 
acute PE 
SBP 150 mm Hg 
HR 80 bpm 
SI 0.5
Oblong, highly mobile, 
length approx. 30 mm
UFH for 3 days, followed by LMWH, follow-up echo at 3th day — per-
sisting RiHT, discharged home at 14th day without RiHT (resolution 
at day 8), in an improved condition
F — female; PE — pulmonary embolism; SBP — systolic blood pressure; HR — heart rate; SI — stroke index [HR/SBP]; rt-PA — recombinant 
tissue plasminogen activator; HIT — heparin-induced thrombocytopenia; M — male; TEE — transesophageal echocardiography; PFO — pa-
tent foramen ovale; BMI — body mass index; MEN I — multiple endocrine neoplasia type 1; LMWH — low-molecular-weight heparin;  
UFH — unfractionated heparin; VKA — vitamin K antagonist; eGFR — estimated glomerular filtration rate; CNS — central nervous system; 
NYHA — New York Heart Association; LVEF — left ventricular ejection fraction
with a control group that included 276 patients with 
acute PE. The mortality rate in the study group was 19%, 
significantly higher compared to the control group (8%). 
In both group, all low risk PE patients survived, and the 
highest mortality rate was noted among hemodynamically 
unstable patients.
Of note, most deaths occurred within 48 hours after the 
diagnosis, which suggests that patients with RiHT should 
be initially managed in an intensive care unit. Similarly to 
our study, predictors of early mortality included indicators 
of hemodynamic instability and clinical parameters (sPESI 
score, SI, hypotension), while morphology of the thrombus 
did not affect prognosis. Similar results were obtained in 
subgroup analyses in the IPER [4] and ICOPER [1] registries.
The choice of appropriate therapy in patients with RiHT 
is still debatable and differs between centres. As suggested 
in the ESC guidelines, anticoagulation only may be not suffi-
cient in these patients [3]. This suggestion is supported by 
the literature data showing the highest mortality in patients 
treated with anticoagulation only [6, 13, 14]. Of note, similar 
mortality was observed in patients treated with surgical 
embolectomy, which was not confirmed by our observations. 
In our study, mortality did not depend on the type of treat-
ment but mostly on the severity of acute PE, and no deaths 
Table 2 (cont.). Clinical characteristics and the clinical course in patients with the right heart thrombus (RiHT)
No. Gender, 
age 
[years]
Characteristics RiHT Treatment and clinical course
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were noted among the patients treated surgically. Previous 
studies did not report detailed data on the clinical condition 
of patients treated surgically, so perhaps this treatment 
was used in critically ill patients, which might explain high 
mortality associated with surgical treatment. This increase 
in mortality is also in contrast with the RIHTER registry data 
which showed a trend towards greater survival in patients 
treated invasively [7]. Thus, the safety of invasive treatment 
has not been clearly established but this therapy should be 
undertaken in patients with RiHT and PFO.
Study limitations
The main study limitation was a low number of patients 
that made it difficult to perform full statistical analysis and 
obtain an appropriate control group. Due to a retrospective 
nature of this analysis, not all echocardiographic parame-
ters and clinical data from the time of the diagnosis were 
available in all cases. No recommendations are available 
to guide treatment in patients with RiHT. Thus, the choice 
of the treatment method often depends on local expertise 
and opinions.
Conclusions
Our findings indicate that 30-day mortality in patients with 
RiHT depends mostly on the patient’s clinical condition. It 
seems that the choice of the treatment method should be 
primarily dictated by the hemodynamic status of the patient. 
Due to the fact that mortality in patients with RiHT occurred 
mostly within 48 hours after the diagnosis, these patients 
should be initially managed in an intensive care unit.
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